The combined therapy, with antidiabetics and weight-loss drugs, such as GLP-1 agonist and SGLT2 inhibitors, has a great significance in the therapy of NASH [117]. This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatohepatitis.